公开(公告)号：EP3252048A4

公开(公告)日：2018-07-18

申请号：EP16742708

申请日：2016-01-25

申请人： SUZHOU SINOVENT PHARMACEUTICALS CO LTD

发明人： WANG ZHONG ,  LI QING

IPC分类号： C07D403/06 ,  A61K31/404 ,  A61P1/16 ,  A61P35/00

CPC分类号： C07D403/06 ,  A61K31/404 ,  A61P1/16 ,  A61P35/00

摘要： The present invention provides a Sunitinib prodrug having formula I, wherein R 12 , R 13 are selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4-15 membered heterocyclyl and 5-15 membered heteroaryl; R 14 is selected from the group consisting of R', OR', SR' and N(R') 2 ; and R' is selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4-15 membered heterocyclyl, 5-15 membered heteroaryl, hydroxyl C 1 -C 6 alkyl, carboxyl C 1 -C 6 alkyl, C 1 -C 6 alkyl amido and phosphate group. The Sunitinib prodrug of the invention provides better pharmacokinetics and pharmacodynamics, better safety and lower toxicity.

公开(公告)号：EP3744722A1

公开(公告)日：2020-12-02

申请号：EP19743504.3

申请日：2019-01-24

申请人： Suzhou Sinovent Pharmaceuticals Co., Ltd.

发明人： WU, Yuchuan ,  HUANG, Shaoqiang ,  CHEN, Xi ,  HU, Yonghan ,  LIU, Xiao

IPC分类号： C07D471/08 ,  C07D487/08 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/496 ,  A61P31/04

摘要： Provided are a β-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need.

公开(公告)号：EP3831822A1

公开(公告)日：2021-06-09

申请号：EP19840459.2

申请日：2019-07-26

申请人： Suzhou Sinovent Pharmaceuticals Co., Ltd.

发明人： PENG, Wei ,  XIAN, Jun ,  HU, Yonghan ,  WU, Yuchuan ,  CHEN, Xi ,  HUANG, Shaoqiang ,  LIU, Xiao ,  LI, Xin ,  HUANG, Bin ,  WU, Dongdong

IPC分类号： C07D401/14 ,  C07D401/12 ,  C07D405/14 ,  C07D405/12 ,  A61K31/4545 ,  A61K31/4433 ,  C07D413/14 ,  A61K31/453 ,  A61K31/444 ,  A61K31/4412 ,  A61K31/497 ,  A61P35/00 ,  A61P35/02

摘要： The present invention provides a novel EZH2 inhibitor compound represented by formula (I) and a use of the inhibitor compound in preventing or treating a disease mediated by EZH2.

公开(公告)号：EP3741759A1

公开(公告)日：2020-11-25

申请号：EP19741276.0

申请日：2019-01-18

申请人： Suzhou Sinovent Pharmaceuticals Co., Ltd.

发明人： WU, Yuchuan ,  CHEN, Xi ,  HUANG, Shaoqiang ,  HU, Yonghan ,  QU, Linhai ,  ZHU, Jinlian ,  LIU, Xiao

IPC分类号： C07D491/048 ,  C07D471/04 ,  C07D471/06 ,  C07D473/00 ,  C07D401/12 ,  C07D231/56 ,  A61K31/437 ,  A61K31/498 ,  A61K31/5025 ,  A61P19/06

摘要： Provided are a heterocyclic compound, a preparation method and the use thereof in medicine, and particularly involved are a heterocyclic compound for preventing and/or treating hypemricemia and gout, a preparation method and the use thereof in medicine. In particular, provided are a compound as shown in formula (I) and/or formula (II) or a tautomer thereof and a pharmaceutically acceptable salt thereof, a preparation method therefor and a method and the use thereof for treating hypemricemia and gout.